Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1.,
Disease:Adenocarcinoma
Product details:
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ATAD2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ATAD2 also known as ATPase family AAA domain-containing protein 2 is a chromatin-associated AAA ATPase. This protein weighs approximately 157 kDa and functions mainly in the cell nucleus. ATAD2 is widely expressed in various tissues with high levels found in the testis indicating its possible role in testicular functions. It shows ATPase activity involving the hydrolysis of ATP which provides energy for chromatin remodeling processes.
Biological function summary
ATAD2 plays a critical role in transcription regulation by remodeling chromatin structure. As part of a complex it interacts with histone acetylation marks on chromatin therefore influencing gene expression. The protein is often involved in the regulation of genes relevant to cell cycle progression. Its interaction with transcriptional regulators highlights its importance in controlling proliferation and other cellular processes.
Pathways
The role of ATAD2 becomes essential in pathways like the cell cycle and the DNA damage response. Through these pathways it interacts with key proteins such as MYC a known regulator of cell growth and it influences the expression of genes involved in cell cycle control. It is important in maintaining genomic stability by ensuring proper chromatin dynamics during DNA replication and repair.
Aberrant expression of ATAD2 associates with cancer progression particularly in breast cancer where it is highly expressed in MCF7 cell lines. It is also implicated in hepatocellular carcinoma where it interacts with cancer-related proteins such as p53 which is a well-known tumor suppressor. These interactions suggest that ATAD2 serves as a potential target for cancer therapies focused on disrupting its interactions or functions in tumor biology.
